South Korea
· Delayed Price · Currency is KRW HLB Genex Statistics
Total Valuation
HLB Genex has a market cap or net worth of KRW 96.88 billion. The enterprise value is 76.09 billion.
| Market Cap | 96.88B |
| Enterprise Value | 76.09B |
Important Dates
The next estimated earnings date is Tuesday, August 12, 2025.
| Earnings Date | Aug 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
HLB Genex has 29.14 million shares outstanding. The number of shares has increased by 10.83% in one year.
| Current Share Class | 29.14M |
| Shares Outstanding | 29.14M |
| Shares Change (YoY) | +10.83% |
| Shares Change (QoQ) | +16.21% |
| Owned by Insiders (%) | 12.56% |
| Owned by Institutions (%) | 2.24% |
| Float | 18.56M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.48 |
| PB Ratio | 3.58 |
| P/TBV Ratio | 4.58 |
| P/FCF Ratio | 1,247.72 |
| P/OCF Ratio | 131.46 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 19.72, with an EV/FCF ratio of 980.04.
| EV / Earnings | -4.10 |
| EV / Sales | 1.95 |
| EV / EBITDA | 19.72 |
| EV / EBIT | n/a |
| EV / FCF | 980.04 |
Financial Position
The company has a current ratio of 0.95, with a Debt / Equity ratio of 1.46.
| Current Ratio | 0.95 |
| Quick Ratio | 0.88 |
| Debt / Equity | 1.46 |
| Debt / EBITDA | 10.22 |
| Debt / FCF | 508.02 |
| Interest Coverage | -0.10 |
Financial Efficiency
Return on equity (ROE) is -64.11% and return on invested capital (ROIC) is -0.52%.
| Return on Equity (ROE) | -64.11% |
| Return on Assets (ROA) | -0.33% |
| Return on Invested Capital (ROIC) | -0.52% |
| Return on Capital Employed (ROCE) | -1.09% |
| Revenue Per Employee | 493.79M |
| Profits Per Employee | -235.03M |
| Employee Count | 79 |
| Asset Turnover | 0.35 |
| Inventory Turnover | 3.95 |
Taxes
In the past 12 months, HLB Genex has paid 1.03 billion in taxes.
| Income Tax | 1.03B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -11.76% in the last 52 weeks. The beta is 0.16, so HLB Genex's price volatility has been lower than the market average.
| Beta (5Y) | 0.16 |
| 52-Week Price Change | -11.76% |
| 50-Day Moving Average | 3,475.40 |
| 200-Day Moving Average | 3,843.65 |
| Relative Strength Index (RSI) | 37.23 |
| Average Volume (20 Days) | 50,605 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, HLB Genex had revenue of KRW 39.01 billion and -18.57 billion in losses. Loss per share was -739.83.
| Revenue | 39.01B |
| Gross Profit | 15.26B |
| Operating Income | -589.56M |
| Pretax Income | -16.71B |
| Net Income | -18.57B |
| EBITDA | 3.86B |
| EBIT | -589.56M |
| Loss Per Share | -739.83 |
Balance Sheet
The company has 64.83 billion in cash and 39.44 billion in debt, giving a net cash position of 25.38 billion or 871.12 per share.
| Cash & Cash Equivalents | 64.83B |
| Total Debt | 39.44B |
| Net Cash | 25.38B |
| Net Cash Per Share | 871.12 |
| Equity (Book Value) | 27.07B |
| Book Value Per Share | 771.45 |
| Working Capital | -4.10B |
Cash Flow
In the last 12 months, operating cash flow was 736.95 million and capital expenditures -659.31 million, giving a free cash flow of 77.64 million.
| Operating Cash Flow | 736.95M |
| Capital Expenditures | -659.31M |
| Free Cash Flow | 77.64M |
| FCF Per Share | 2.66 |
Margins
Gross margin is 39.11%, with operating and profit margins of -1.51% and -47.60%.
| Gross Margin | 39.11% |
| Operating Margin | -1.51% |
| Pretax Margin | -42.85% |
| Profit Margin | -47.60% |
| EBITDA Margin | 9.89% |
| EBIT Margin | -1.51% |
| FCF Margin | 0.20% |
Dividends & Yields
HLB Genex does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.83% |
| Shareholder Yield | n/a |
| Earnings Yield | -19.17% |
| FCF Yield | 0.08% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on March 19, 2018. It was a forward split with a ratio of 2.
| Last Split Date | Mar 19, 2018 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
HLB Genex has an Altman Z-Score of 0.55 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.55 |
| Piotroski F-Score | 6 |